Parkman Healthcare Partners LLC
Known title: 10% OwnerCIK: 0001777015
Parkman Healthcare Partners LLC's purchase track record
Parkman Healthcare Partners LLC has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/6/2025 | SPRB | $9K | -37.0% | -51.7% | -1.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SPRB | ▲ Buy | Open Market | 256 | $5K | 10/6/2025 | View on chart |
| SPRB | ▼ Sell | Open Market | 232 | $4K | 10/6/2025 | View on chart |
| SPRB | ▼ Sell | Open Market | 25 | $436 | 10/6/2025 | View on chart |
| SPRB | ▲ Buy | Open Market | 256 | $5K | 10/6/2025 | View on chart |
| SPRB | ▼ Sell | Open Market | 232 | $4K | 10/6/2025 | View on chart |
| SPRB | ▼ Sell | Open Market | 25 | $436 | 10/6/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences
Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.